GeneDx Holdings Launches Program to Improve Pediatric Epilepsy Diagnosis Through Genetic Testing

GeneDx Launches Patient Access Program to Transform Pediatric Epilepsy Diagnosis

GeneDx Holdings has recently unveiled a groundbreaking Patient Access Program aimed at revolutionizing the diagnosis of pediatric epilepsy. In collaboration with Biogen, Praxis Precision Medicines, and Stoke Therapeutics, this initiative addresses a significant hurdle that many families face: the lengthy diagnostic journey that often spans 5 to 8 years. For numerous children suffering from epilepsy, access to definitive genetic diagnoses remains limited. By focusing on whole exome sequencing—the comprehensive analysis of the protein-coding regions of genes—GeneDx aims to provide a crucial tool in identifying the genetic underpinnings of this complex disorder.

The need for this program arises from the fact that over 700 genes are linked to seizures, yet most commercial gene panels only evaluate a fraction of these, typically covering less than 50%. GeneDx's patient access initiative seeks to enhance the availability of whole exome sequencing, which has demonstrated a markedly higher diagnostic yield compared to traditional gene panels. Specifically, whole exome testing can deliver a genetic diagnosis for nearly 25% of seizure patients, as opposed to just 19% from conventional methods. This disparity highlights the urgency for improved testing protocols, particularly given the National Society of Genetic Counselors and the American Epilepsy Society's endorsements of exome testing as a first-line approach for unexplained epilepsy.

Melanie Duquette, Chief Growth Officer at GeneDx, underscores the program's dual purpose: to provide answers for families grappling with the uncertainties of epilepsy and to contribute to the broader research landscape. With nearly half a million children under 18 diagnosed with epilepsy in the U.S., the initiative not only aims to streamline the diagnostic process but also enriches GeneDx's extensive database of over 700,000 exome and genome results. This wealth of information will enhance research into gene-disease relationships for seizure-related conditions, ultimately paving the way for more personalized therapies and treatments in the future. As GeneDx continues to prioritize equitable access to genetic testing, it stands at the forefront of a movement that promises to transform pediatric epilepsy care.

In addition to addressing the diagnostic challenges faced by families, GeneDx’s initiative highlights the critical role of collaboration within the biopharma sector. By partnering with key industry players, the program amplifies resources and expertise, enhancing the potential for innovative solutions in genetic testing. This collaborative approach not only benefits patients but also strengthens the research community's capacity to uncover new insights into epilepsy and related disorders.

As GeneDx implements this program, it sets a new standard for accessibility in genetic testing, reinforcing its commitment to improving health outcomes for children with epilepsy and their families. This initiative marks a significant step forward in bridging the gap between genetic insights and clinical application, establishing a model that other companies in the industry may seek to replicate.